Vanguard Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $7B | Buy |
9,075,153
+26,884
| +0.3% | +$18.3M | 0.1% | 170 |
|
|
2025
Q3 | $5.09B | Sell |
9,048,269
-375,779
| -4% | -$212M | 0.08% | 253 |
|
|
2025
Q2 | $4.95B | Buy |
9,424,048
+16,157
| +0.2% | +$9.02M | 0.08% | 246 |
|
|
2025
Q1 | $5.97B | Buy |
9,407,891
+121,545
| +1% | +$83.6M | 0.11% | 165 |
|
|
2024
Q4 | $6.61B | Sell |
9,286,346
-33,944
| -0.4% | -$28.5M | 0.12% | 149 |
|
|
2024
Q3 | $9.8B | Buy |
9,320,290
+326,320
| +4% | +$363M | 0.18% | 96 |
|
|
2024
Q2 | $9.45B | Buy |
8,993,970
+63,729
| +0.7% | +$61.8M | 0.18% | 95 |
|
|
2024
Q1 | $8.6B | Buy |
8,930,241
+91,956
| +1% | +$87.4M | 0.17% | 103 |
|
|
2023
Q4 | $7.76B | Buy |
8,838,285
+39,780
| +0.5% | +$32.8M | 0.17% | 104 |
|
|
2023
Q3 | $7.24B | Sell |
8,798,505
-58,533
| -0.7% | -$46M | 0.18% | 96 |
|
|
2023
Q2 | $6.36B | Buy |
8,857,038
+4,917
| +0.1% | +$3.79M | 0.15% | 109 |
|
|
2023
Q1 | $7.27B | Buy |
8,852,121
+129,673
| +1% | +$97.8M | 0.19% | 95 |
|
|
2022
Q4 | $6.29B | Buy |
8,722,448
+74,323
| +0.9% | +$54.8M | 0.17% | 110 |
|
|
2022
Q3 | $5.96B | Buy |
8,648,125
+77,380
| +0.9% | +$48.7M | 0.18% | 100 |
|
|
2022
Q2 | $5.07B | Buy |
8,570,745
+210,415
| +3% | +$137M | 0.14% | 124 |
|
|
2022
Q1 | $5.84B | Buy |
8,360,330
+201,815
| +2% | +$128M | 0.14% | 122 |
|
|
2021
Q4 | $5.15B | Buy |
8,158,515
+87,234
| +1% | +$53.6M | 0.12% | 152 |
|
|
2021
Q3 | $4.88B | Buy |
8,071,281
+101,621
| +1% | +$63.1M | 0.12% | 144 |
|
|
2021
Q2 | $4.45B | Sell |
7,969,660
-30,752
| -0.4% | -$15.6M | 0.11% | 158 |
|
|
2021
Q1 | $3.79B | Buy |
8,000,412
+69,192
| +0.9% | +$33.7M | 0.1% | 174 |
|
|
2020
Q4 | $3.83B | Sell |
7,931,220
-57,008
| -0.7% | -$30.8M | 0.11% | 160 |
|
|
2020
Q3 | $4.47B | Buy |
7,988,228
+143,233
| +2% | +$86.8M | 0.15% | 117 |
|
|
2020
Q2 | $4.89B | Buy |
7,844,995
+1,429,765
| +22% | +$812M | 0.17% | 99 |
|
|
2020
Q1 | $3.13B | Buy |
6,415,230
+162,927
| +3% | +$67.2M | 0.13% | 143 |
|
|
2019
Q4 | $2.35B | Buy |
6,252,303
+47,835
| +0.8% | +$16.1M | 0.08% | 261 |
|
|
2019
Q3 | $1.72B | Buy |
6,204,468
+125,121
| +2% | +$37M | 0.06% | 338 |
|
|
2019
Q2 | $1.9B | Buy |
6,079,347
+54,247
| +0.9% | +$18.1M | 0.07% | 295 |
|
|
2019
Q1 | $2.47B | Buy |
6,025,100
+127,067
| +2% | +$52.3M | 0.1% | 203 |
|
|
2018
Q4 | $2.2B | Buy |
5,898,033
+143,106
| +2% | +$52.4M | 0.1% | 195 |
|
|
2018
Q3 | $2.33B | Buy |
5,754,927
+75,868
| +1% | +$28.9M | 0.09% | 213 |
|
|
2018
Q2 | $1.96B | Buy |
5,679,059
+71,435
| +1% | +$22.3M | 0.08% | 246 |
|
|
2018
Q1 | $1.93B | Buy |
5,607,624
+113,573
| +2% | +$39.5M | 0.08% | 241 |
|
|
2017
Q4 | $2.07B | Buy |
5,494,051
+94,540
| +2% | +$38.3M | 0.09% | 233 |
|
|
2017
Q3 | $2.41B | Buy |
5,399,511
+129,053
| +2% | +$61.4M | 0.11% | 179 |
|
|
2017
Q2 | $2.59B | Buy |
5,270,458
+148,962
| +3% | +$65.2M | 0.13% | 150 |
|
|
2017
Q1 | $1.98B | Buy |
5,121,496
+199,975
| +4% | +$74.1M | 0.1% | 197 |
|
|
2016
Q4 | $1.81B | Buy |
4,921,521
+110,090
| +2% | +$41.9M | 0.1% | 208 |
|
|
2016
Q3 | $1.93B | Buy |
4,811,431
+32,245
| +0.7% | +$12.9M | 0.11% | 178 |
|
|
2016
Q2 | $1.67B | Buy |
4,779,186
+92,467
| +2% | +$35.6M | 0.1% | 205 |
|
|
2016
Q1 | $1.69B | Buy |
4,686,719
+129,032
| +3% | +$53.2M | 0.11% | 186 |
|
|
2015
Q4 | $2.47B | Buy |
4,557,687
+131,565
| +3% | +$71.3M | 0.17% | 116 |
|
|
2015
Q3 | $2.06B | Buy |
4,426,122
+130,937
| +3% | +$70.3M | 0.15% | 126 |
|
|
2015
Q2 | $2.19B | Buy |
4,295,185
+108,784
| +3% | +$53.1M | 0.15% | 129 |
|
|
2015
Q1 | $1.89B | Buy |
4,186,401
+175,718
| +4% | +$74.5M | 0.13% | 158 |
|
|
2014
Q4 | $1.65B | Buy |
4,010,683
+151,130
| +4% | +$59.4M | 0.12% | 167 |
|
|
2014
Q3 | $1.39B | Sell |
3,859,553
-54,150
| -1% | -$18.1M | 0.11% | 182 |
|
|
2014
Q2 | $1.11B | Sell |
3,913,703
-1,186
| -0% | -$352K | 0.09% | 241 |
|
|
2014
Q1 | $1.18B | Buy |
3,914,889
+129,159
| +3% | +$39.8M | 0.1% | 212 |
|
|
2013
Q4 | $1.04B | Buy |
3,785,730
+91,460
| +2% | +$26.3M | 0.09% | 229 |
|
|
2013
Q3 | $1.16B | Sell |
3,694,270
-583,340
| -14% | -$153M | 0.11% | 172 |
|
|
2013
Q2 | $962M | Buy |
+4,277,610
| New | +$996M | 0.1% | 197 |
|
Other funds holding REGN
Vanguard Group's REGN Position: Q4 2025 in Review
Vanguard Group increased its Regeneron Pharmaceuticals (REGN) stake by 0.3% in Q4 2025, buying an estimated $18.3M and bringing the position to 9,075,153 shares worth $7B. The position accounts for 0.1% of the portfolio, ranked #170.
Vanguard Group first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $9.8B in Q3 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.
- Vanguard Group held 9,075,153 shares of Regeneron Pharmaceuticals worth $7B as of Q4 2025.
- Vanguard Group bought 26,884 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $18.3M.
- Regeneron Pharmaceuticals made up 0.1% of Vanguard Group's portfolio in Q4 2025, its #170 holding.
- Vanguard Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Regeneron Pharmaceuticals position peaked at $9.8B in Q3 2024.
- 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.